Leap Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Cypherpunk Technologies

08/11/2022 11:23

* Leap Therapeutics Inc  LPTX.OQ   LPTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Leap Therapeutics
Inc is
for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $4​, above​ its last closing price of $0.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.10       -0.10      -0.15     Missed  -56.2
 Mar. 31 2022  -0.10       -0.10      -0.09     Beat    10
 Dec. 31 2021  -0.12       -0.11      -0.10     Beat    9.1​
 Sep. 30 2021  -0.10       -0.11      -0.14     Missed  -25
 ​​Jun.        -0.13       -0.12      -0.12     Met     4
 30 2021                                                
 Mar. 31 2021  -0.11       -0.11      -0.12     Missed  -13.2​
 Dec. 31 2020  -0.09       -0.09      -0.09     Met     -2.3
 Sep. 30 2020  -0.12       -0.13      -0.09     Beat    29.7
 This summary was machine generated November 8 at 11:23 GMT.  All
figures in US dollars  unless otherwise stated